- Home
- AUTL
as 01-21-2025 4:00pm EST
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 590.8M | IPO Year: | 2018 |
| Target Price: | $10.20 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.07 - $7.37 | Next Earning Date: | 03-13-2025 |
| Revenue: | $10,091,000 | Revenue Growth: | 82.71% |
| Revenue Growth (this year): | 851.83% | Revenue Growth (next year): | 264.18% |
Latest Autolus Therapeutics plc News
AUTL Breaking Stock News: Dive into AUTL Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
GlobeNewswire
9 days ago
Autolus Therapeutics Provides Business Updates and 2025 Overview
Insider Monkey
23 days ago
Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now?
GlobeNewswire
a month ago
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Insider Monkey
2 months ago
Autolus Therapeutics plc (AUTL): A Bull Case Theory
GlobeNewswire
2 months ago
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
TipRanks
2 months ago
Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs
MT Newswires
2 months ago
Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7
Compare AUTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUTL Autolus Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.